DIDS, a VDAC1 oligomerization inhibitor, was used to surmount PTX resistance in GC cells with high VDAC1 expression to evaluate the clinical treatment significance of targeting EV-derived VDAC1 protein in GC 43
6 The role of GSH as a skin-lightening agent was accidentally discovered as a side effect in the treatment of chronic diseases using glutathione
A 2012 systematic review and meta-analysis, along with a 2013 controlled clinical trial, showed that ALA is an effective drug in the treatment of diabetic neuropathy, which affects about 50 percent of people with diabetes
Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives
Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: a network meta-analysis
[2] [6] The medication is not recommended for patients with severe gastroparesis and requires careful monitoring in patients with diabetic retinopathy due to potential worsening with rapid glucose improvement
